福安药业(300194) - 2025 Q4 - 年度业绩预告

Financial Performance - The net profit attributable to shareholders is expected to be between 70 million and 100 million yuan, a decrease of 64.26% compared to the same period last year, which was 279.83 million yuan [4]. - The net profit after deducting non-recurring gains and losses is projected to be between 52 million and 78 million yuan, down 69.83% from 258.50 million yuan in the previous year [4]. - The significant decline in performance is attributed to the nationwide implementation of drug procurement policies, leading to a substantial decrease in sales prices of main products and ongoing pressure on profit margins [7]. - The acquisition of Ningbo Tianheng Pharmaceutical has resulted in a notable decline in its operating performance, with an estimated goodwill impairment of around 150 million yuan expected to be recognized [7]. - After excluding the goodwill impairment, the net profit attributable to shareholders is expected to be between 220 million and 250 million yuan [7]. Risk and Reporting - The data provided is preliminary and has not been audited, highlighting the need for investors to be aware of risks and to invest rationally [8]. - The specific data will be detailed in the company's 2025 annual report [9].